RT Journal Article
SR Electronic
T1 Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1911
OP 1918
DO 10.21873/anticanres.15668
VO 42
IS 4
A1 MANUEL NEUBERGER
A1 JANINA SKLADNY
A1 NORA GOLY
A1 FREDERIK WESSELS
A1 CHRISTEL WEIß
A1 LUISA EGEN
A1 PHILIPP ERBEN
A1 MATTHIAS GROß-WEEGE
A1 BRITTA GRÜNE
A1 FRIEDRICH HARTUNG
A1 JONAS HERRMANN
A1 PATRICK HONECK
A1 JONAS JARCZYK
A1 KARL-FRIEDRICH KOWALEWSKI
A1 JULIA MÜHLBAUER
A1 KATJA NITSCHKE
A1 MALIN NIENTIEDT
A1 MARGARETE THERESA WALACH
A1 FRANK WALDBILLIG
A1 NIKLAS WESTHOFF
A1 JOST VON HARDENBERG
A1 MAXIMILIAN KRIEGMAIR
A1 THOMAS S. WORST
A1 PHILIPP NUHN
YR 2022
UL http://ar.iiarjournals.org/content/42/4/1911.abstract
AB Background/Aim: To assess the baseline inflammatory markers modified Glasgow Prognostic Score (mGPS), systemic immune-inflammation index (SII), and neutrophile-to-lymphocyte ratio (NLR) as pragmatic tools for predicting response to chemohormonal therapy (docetaxel plus ADT) and prognosis in men with metastatic hormone-sensitive prostate cancer (mHSPC). Patients and Methods: Male patients who received docetaxel at a tertiary university care center between 2014 and 2019 were screened for completion of 6 cycles. NLR, SII, mGPS, overall survival (OS), three-year survival, and radiologic response were assessed. Complete response (CR), partial response (PR), and stable disease (SD) were analyzed alone and in combination. Results: Thirty-six mHSPC-patients were included. In thirty patients, baseline mGPS was assessed and was either 0 (n=22) or 2 (n=8). In Cochran-Armitage Trend Test, mGPS showed significant association with the combined radiologic endpoint of “CR, PR, or SD” (p=0.01), three-year survival (p=0.02), and OS (p<0.01). Next to prostate-specific antigen (PSA) (HR per 100 units 1.16, 95%CI=1.04-1.30, p<0.01), NLR (HR=1.31, 95%CI=1.03-1.66, p=0.03), and mGPS (2 vs. 0, HR=6.53, 95%CI=1.6-27.0, p<0.01) at baseline showed significant association with OS in univariable cox regression. However, mGPS remained the only independent predictor for OS in multivariable cox regression (p<0.01) and for the combined radiologic endpoint of “CR, PR or SD” (p=0.01) in multivariable logistic regression. SII showed no statistical relevance. Conclusion: Baseline mGPS seems to be a pragmatic tool for clinical decision-making in patients with mHSPC in daily routine.